 |
Wong Tien Y.; Haskova Zdenka; Asik Kemal; Baumal Caroline R.; Csaky Karl G.; Eter Nicole; Ives Jane A.; Jaffe Glenn J.; Korobelnik Jean-François; Lin Hugh; Murata Toshinori; Ruamviboonsuk Paisan; Schlottmann Patricio G.; Seres András I.; Silverman David; Sun Xiaodong; Tang Yannan; Wells John A.; Hee Yoon Young; Wykoff Charles C.; Kollaborációs szervezet: YOSEMITE and RHINE Investigators; NEM RÉSZLETEZETT; Papp András; Tóth-Molnár Edit:
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
OPHTHALMOLOGY, 131 (6).
pp. 708-723.
ISSN 0161-6420
(2024)
Jackson Timothy L.; Slakter Jason; Buyse Marc; Wang Kun; Dugel Pravin U.; Wykoff Charles C.; Boyer David S.; Gerometta Michael; Baldwin Megan E.; Price Clare F.; Kollaborációs szervezet: Opthea Study Group Investigator; Facskó Andrea; Kerényi Ágnes; Papp András; Vogt Gábor; et al.:
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.
OPHTHALMOLOGY, 130 (6).
pp. 588-597.
ISSN 0161-6420
(2023)
Wykoff Charles C.; Abreu Francis; Adamis Anthony P.; Basu Karen; Eichenbaum David A.; Haskova Zdenka; Lin Hugh; Loewenstein Anat; Mohan Shaun; Pearce Ian A.; Sakamoto Taiji; Schlottmann Patricio G.; Papp András; Tóth-Molnár Edit; Kollaborációs szervezet: YOSEMITE and RHINE Investigators:
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
LANCET, 399 (10326).
pp. 741-755.
ISSN 0140-6736
(2022)
![[Fel]](/style/images/multi_up.png)
Vissza
